

**NOTICE FOR ELEVENTH (11<sup>TH</sup>) ANNUAL GENERAL MEETING  
THROUGH VIDEO CONFERENCE**

**NOTICE** is hereby given that the **Eleventh (11<sup>th</sup>) Annual General Meeting (“AGM”)** of **FinOrion Pharma India Private Limited - the ‘Company’** will be held **Monday, September 19, 2022**, at **Registered office address - 501, A Wing, Everest Chambers Marol Naka, Andheri Kurla Road, Andheri (E) Mumbai City Maharashtra 400059 India, at 12:00 noon IST i.e., 9.30 a.m. FI time** via video conference (i.e., through Microsoft teams) pursuant to General Circular no. 2/2022 dated 5<sup>th</sup> May 2022 issued by Ministry of Corporate Affairs, read with other related circulars in this regards, to transact the following businesses:

❖ **ORDINARY BUSINESS:**

1. To receive, consider and adopt the Audited Standalone Financial Statements of the Company comprising of the Audited Balance Sheet as on March 31, 2022, the Statement of Profit and Loss and Cash Flow Statement for the year ended on that date along with notes and the Reports of the Board of Directors and Auditors thereon.

• **Kindly confirm your availability and accessibility of participation through video conferencing on following contacts:**

- **Email ID** : [Samrudhi.Utturkar@orion.fi](mailto:Samrudhi.Utturkar@orion.fi)
- **Telephone/Mobile No.** : +91 99207 87222
- **Video Conference Details** : Directors, Members & Auditors may connect via Microsoft teams

**By order of the Board**  
**FinOrion Pharma India Private Limited**

DocuSigned by:

*Samrudhi Utturkar*



Signer Name: Samrudhi Utturkar  
Signing Reason: I approve this document  
Signing Time: 22-Aug-2022 | 4:40 PM EEDT

**Samrudhi Mangesh Utturkar** BBA8BD895

**Director**

**DIN: 08162610**

**Address: A/302, Vakratunda Palace, Tank Road, Opp. Lodha Imperia, Bhandup West, Mumbai - 400078**

**Email ID: [samrudhi.utturkar@orion.fi](mailto:samrudhi.utturkar@orion.fi)**

**Date: August 22, 2022**

**Place: Mumbai**

**FinOrion Pharma India Private Limited**

Registered Office: 501, 5th Floor, A wing, Everest Chambers

Marol Naka, Andheri-Kurla Road, Andheri (East),

Mumbai - 400 059, India

Tel: +91 8104964640

Email: [contact.india@orion.fi](mailto:contact.india@orion.fi)

CIN No: U74120MH2011PTC225361

[www.orionpharma.in](http://www.orionpharma.in)

**❖ NOTES:**

1. In view of the COVID 19 pandemic, the Ministry of Corporate Affairs vide its General Circular no. 2/2022 dated 5<sup>th</sup> May 2022, read with General Circular No. 20/2020 dated 5<sup>th</sup> May, 2020, General Circular No. 2/2021 dated 13<sup>th</sup> January 2021, General Circular No. 19/2021 dated 8<sup>th</sup> December, 2021 and General Circular No. 21/2021 dated 14<sup>th</sup> December, 2021 (collectively referred to as 'Circulars'), has introduced certain measures enabling companies to convene their Annual General Meetings (AGM/ Meeting) through Video Conferencing (VC) or Other Audio Visual Means (OAVM) and also send notice of the Meeting and other correspondences related thereto, through electronic mode. In compliance with the said requirements of the MCA Circulars, electronic copy of the Notice along with the Annual Report for the Financial Year ended 31<sup>st</sup> March, 2022 consisting of financial statements including Board's Report, Auditors' Report and other documents required to be attached therewith (Collectively referred to as Notice) have been sent only to those members whose e- mail ids are registered with the Company through electronic means and no physical copy of the Notice has been sent by the Company to any member. The Notice shall be hosted on the website of the Company.
2. Members are requested to intimate the change(s), if any, of the e-mail addresses with the company at the earliest addressed to Mrs. Samrudhi Mangesh Utturkar, Director of the Company at email id: [Samrudhi.Utturkar@orion.fi](mailto:Samrudhi.Utturkar@orion.fi).
3. As required under the provision of Section 136 of Companies Act, 2013, the Audited financial statements are annexed herewith this notice.
4. Annual General Meeting can be held via a shorter notice with the consent of all the members.
5. Attendance of members joining through Video Conferencing mode shall be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.
6. Auditors are invited to attend this Annual General Meeting held through Video Conferencing.
7. The Chairman/Chairperson is requested to take a roll call to ensure that they can completely and clearly see and communicate with all the participants and that no one other than the concerned authorized participant is attending the Annual General Meeting through electronic mode and ascertain the quorum necessary in accordance with the Articles of Association of the Company and the Companies Act, 2013.
8. In case if any member proposes to inspect any document before or during the meeting, then, the member is required to inform the same to the Company through e-mail at the below mentioned mail address and the same shall be provided to the members through e-mail only. The said emails shall only to be sent to the designated email address i.e., [Samrudhi.Utturkar@orion.fi](mailto:Samrudhi.Utturkar@orion.fi).

**FinOrion Pharma India Private Limited**

Registered Office: 501, 5th Floor, A wing, Everest Chambers  
Marol Naka, Andheri-Kurla Road, Andheri (East),  
Mumbai - 400 059, India  
Tel: +91 8104964640  
Email: [contact.india@orion.fi](mailto:contact.india@orion.fi)  
CIN No: U74120MH2011PTC225361  
[www.orionpharma.in](http://www.orionpharma.in)

9. The Meeting shall be deemed to be held at the Registered office address - 501, A Wing, Everest Chambers Marol Naka, Andheri Kurla Road, Andheri (E) Mumbai City Maharashtra 400059 India.
  10. Corporate shareholders are requested to send a duly certified true copy of the Board Resolution authorizing their representative to attend and vote at the Meeting.
  11. The soft copy of registers as required to be maintained in accordance with the provisions of the Companies Act, 2013, will be made available for e-inspection at the request of the members at the General Meeting.
  12. Generally, a member entitled to attend and vote at the meeting is entitled to appoint a proxy to attend and vote on a poll instead of himself and the proxy need not be a member of the Company. Since this AGM is being held through VC / OAVM pursuant to the MCA Circulars, physical attendance of members has been dispensed with. Accordingly, the facility for appointment of proxies by the members will not be available for the AGM and hence the Proxy Form and Attendance Slip are not annexed hereto.
  13. An invitation to join the meeting via videoconference through Microsoft teams shall be sent to all the shareholders and their representatives on their e-mail addresses registered with the Company.
- ❖ **Instructions for Members for participating in the AGM through VC facility are as under:**
14. The members may join the meeting through Microsoft teams Meeting link, the Meeting Id for which shall be shared with all the Members separately through a mail.
  15. Members are required to download Microsoft team's application or directly join via link provided in their systems and to click on "Join a meeting" option as shown on the home page of that app.
  16. Shareholders will be required to switch on the video facility during the Meeting. Further, Members will be required to use Internet with a good speed to avoid any disturbance during the meeting.
  17. For any further assistance in joining and participating in meeting directly addressed to Mrs. Samrudhi Mangesh Utturkar, Director of the Company at email id: [Samrudhi.Utturkar@orion.fi](mailto:Samrudhi.Utturkar@orion.fi).

**FinOrion Pharma India Private Limited**

Registered Office: 501, 5th Floor, A wing, Everest Chambers  
Marol Naka, Andheri-Kurla Road, Andheri (East),  
Mumbai - 400 059, India  
Tel: +91 8104964640  
Email: [contact.india@orion.fi](mailto:contact.india@orion.fi)  
CIN No: U74120MH2011PTC225361  
[www.orionpharma.in](http://www.orionpharma.in)

18. The facility for joining the meeting shall be kept open at least 15 minutes before the time scheduled to start the meeting and shall not be closed till the expiry of 15 minutes after such scheduled time.

**By order of the Board**  
**FinOrion Pharma India Private Limited**

DocuSigned by:

*Samrudhi Utturkar*



Signer Name: Samrudhi Utturkar  
Signing Reason: I approve this document  
Signing Time: 22-Aug-2022 | 4:41 PM EEDT

7224874C900E499CAC61BB4EBA8BD895

**Samrudhi Mangesh Utturkar**

**Director**

**DIN: 08162610**

**Address: A/302, Vakratunda Palace, Tank Road, Opp. Lodha Imperia, Bhandup West, Mumbai - 400078**

**Email ID: [samrudhi.utturkar@orion.fi](mailto:samrudhi.utturkar@orion.fi)**

**Date: August 22, 2022**

**Place: Mumbai**

**CC:**

- 1. All Directors of the Company;**
- 2. Statutory Auditor(s) of the Company.**

**FinOrion Pharma India Private Limited**

Registered Office: 501, 5th Floor, A wing, Everest Chambers

Marol Naka, Andheri-Kurla Road, Andheri (East),

Mumbai - 400 059, India

Tel: +91 8104964640

Email: [contact.india@orion.fi](mailto:contact.india@orion.fi)

CIN No: U74120MH2011PTC225361

[www.orionpharma.in](http://www.orionpharma.in)